DNTH CFO exercises options, sells 8,224 shares
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options and sold the resulting shares.
Rhea-AI Filing Summary
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options and sold the resulting shares. He exercised options for 8,224 shares of common stock at an exercise price of $17.88 per share, then sold 8,224 shares of common stock at a weighted average price of $89.84 per share.
The filing shows 71,776 stock options remaining following the derivative transaction and 0 shares of common stock held directly after the sale. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 8,224 shares ($592K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Savitz Ryan
Role
EVP, CFO & CBO
Sold
8,224 shs ($739K)
Approx. gross sale proceeds
$739K
Approx. exercise cost
$147K
Approx. pre-tax spread
$592K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 8,224 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,224 | $17.88 | $147K |
| Sale | Common Stock | 8,224 | $89.84 | $739K |
Holdings After Transaction:
Stock Option (Right to Buy) — 71,776 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.75 to $89.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Options exercised: 8,224 shares
Option exercise price: $17.88 per share
Shares sold: 8,224 shares
+5 more
8 metrics
Options exercised
8,224 shares
Stock option exercise into common stock
Option exercise price
$17.88 per share
Exercise price of stock options
Shares sold
8,224 shares
Common stock sold in open-market transactions
Weighted average sale price
$89.84 per share
Weighted average price for 8,224 shares sold
Sale price range
$89.75–$89.95 per share
Range of prices for multiple sale transactions
Options remaining
71,776 options
Total derivative securities following transaction
Common stock after sale
0 shares
Directly held common shares following transactions
Option expiration date
January 23, 2034
Expiration of stock option award
Key Terms
Rule 10b5-1 trading plan, weighted average price, stock option (right to buy), vesting, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock option (right to buy) financial
"Security title: Stock Option (Right to Buy)"
vesting financial
"shares of common stock underlying this stock option award vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did DNTH executive Ryan Savitz report?
Ryan Savitz reported exercising stock options and immediately selling the resulting shares. He exercised options for 8,224 Dianthus Therapeutics shares and sold 8,224 common shares in open-market transactions, reflecting an exercise-and-sell pattern rather than a long-term share accumulation.
What is the size of the DNTH option exercise reported by Ryan Savitz?
The filing shows an option exercise covering 8,224 underlying shares of Dianthus Therapeutics common stock. These options carried a $17.88 per share exercise price, and the award vests in equal monthly installments over four years starting January 1, 2024.
AI-generated analysis. How Rhea-AI works. Not financial advice.
